Nordic Nanovector ASA publishes 2020 Annual Report

Rhea-AI Summary

On March 26, 2021, the Board of Directors of Nordic Nanovector ASA approved its 2020 financial statements. The annual report highlights Nordic Nanovector's commitment to developing innovative cancer therapies, particularly its lead candidate, Betalutin®, aimed at treating non-Hodgkin's lymphoma. The non-Hodgkin's lymphoma market is projected to reach USD 26 billion by 2028. Nordic Nanovector retains global marketing rights for Betalutin® and plans to actively engage in its commercialization in major markets. The annual report is available on the company's website.

Positive

• Nordic Nanovector's lead candidate, Betalutin®, targets non-Hodgkin's lymphoma, a market projected to be worth USD 26 billion by 2028.
• The company retains global marketing rights to Betalutin® and intends to participate in its commercialization.

Negative

• None.

OSLO, Norway, March 29, 2021 /PRNewswire/ -- On 26 March 2021, the Board of Directors of Nordic Nanovector ASA approved the Company's financial statements for 2020. The Company's 2020 Annual Report is attached and available on Nordic Nanovector ASA's website: www.nordicnanovector.com.

For further information, please contact:

IR enquiries

Malene Brondberg, CFO
Cell: +44 7561 431 762
Email: ir@nordicnanovector.com

Media Enquiries

Mark Swallow/Frazer Hall/David Dible (Citigate Dewe Rogerson)
Tel: +44 203 926 8535
Email: nordicnanovector@citigatedewerogerson.com

About Nordic Nanovector:

Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers. Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37-targeting antibody-radionuclide-conjugate designed to advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 26 billion by 2028. Nordic Nanovector retains global marketing rights to Betalutin® and intends to actively participate in the commercialisation of Betalutin® in the US and other major markets.

Further information can be found at www.nordicnanovector.com.

CONTACT:

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/nordic-nanovector/r/nordic-nanovector-asa-publishes-2020-annual-report,c3315434

The following files are available for download:

https://mb.cision.com/Main/9819/3315434/1393628.pdf

Release

View original content:http://www.prnewswire.com/news-releases/nordic-nanovector-asa-publishes-2020-annual-report-301257277.html

SOURCE Nordic Nanovector

FAQ

What does Nordic Nanovector ASA focus on?

Nordic Nanovector ASA focuses on developing innovative therapies for cancer, particularly targeted treatments for haematological cancers.

What is Betalutin® and its significance?

Betalutin® is a novel CD37-targeting antibody-radionuclide-conjugate designed for treating non-Hodgkin's lymphoma.

What was approved by Nordic Nanovector's Board on March 26, 2021?

On March 26, 2021, the Board approved the company's financial statements for the year 2020.

Where can I find Nordic Nanovector's 2020 Annual Report?

The 2020 Annual Report of Nordic Nanovector is available on their official website.

What is the market potential for non-Hodgkin's lymphoma?

The non-Hodgkin's lymphoma market is expected to reach nearly USD 26 billion by 2028.